Related Experiment Video

Updated: Jun 20, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.3K

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells

K Bauer1, E Hadzijusufovic1,2,3, S Cerny-Reiterer1,2

  • 1Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

Veterinary and Comparative Oncology
|August 11, 2016
PubMed

Insights

CD30 is a promising target for canine mast cell neoplasms. Interleukin-4 (IL-4) downregulates CD30, potentially reducing treatment effectiveness, but drug combinations show promise.

Area of Science:

  • Comparative oncology
  • Immunology
  • Veterinary medicine

Background:

  • CD30 is a therapeutic target in human mast cell (MC) neoplasms.
  • Canine MC neoplasms represent a comparative oncology model for human disease.

Purpose of the Study:

  • To investigate CD30 expression and regulation in neoplastic canine MC.
  • To evaluate the efficacy of CD30-targeting therapies and identify resistance mechanisms.

Main Methods:

  • Utilized canine mastocytoma cell lines (NI-1, C2) and immunomodulatory cytokines (IL-2, IL-4, IL-5, IL-6, IL-13, SCF).
  • Assessed CD30 expression, brentuximab vedotin effects, and drug synergy (masitinib, PKC412).

Main Results:

  • Interleukin-4 (IL-4) significantly downregulated CD30 expression in both cell lines.
  • Brentuximab vedotin induced growth inhibition and apoptosis, but IL-4 pre-incubation reduced its efficacy.
  • Brentuximab vedotin synergized with masitinib and PKC412 to overcome IL-4-mediated resistance.

Conclusions:

  • CD30 is a novel therapeutic target in neoplastic canine MC.
  • IL-4-mediated CD30 downregulation presents a resistance mechanism to brentuximab vedotin.
  • Combination therapies involving brentuximab vedotin offer a strategy to overcome resistance in canine MC neoplasms.
Keywords:
CD30IL-4PKC412brentuximab vedotincanine mastocytomamasitinib

More Related Videos

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

21.0K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...